Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Lille
With
AstraZeneca
Age
40–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Female or male subjects aged 40-75 years Documented COPD in stable condition FEV1 between 30 % and 70 % predicted (post bronchodilator) Significant dyspnea with a mMRC dyspnea scale
You may not be if
History or current diagnosis of asthma or ACO (asthma-COPD overlap syndrome)
Respiratory infection or COPD exacerbation within 6 weeks (2 months if it resulted in hospitalization) prior to screening
